<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01549704</url>
  </required_header>
  <id_info>
    <org_study_id>SM1-UG-11</org_study_id>
    <nct_id>NCT01549704</nct_id>
  </id_info>
  <brief_title>Effect of Adductor-Canal-Blockade on High Pain Responders After Total Knee Arthroplasty</brief_title>
  <official_title>Effect of Adductor-Canal-Blockade on High Pain Responders the 1. or 2. Postoperative Day After Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Adductor-Canal-Blockade (ACB) is superior
      to placebo when it comes to analgetic efficacy in high pain responders after Total Knee
      Arthroplasty (TKA). High pain responders are defined as patients reporting VAS &gt; 60 during
      knee flexion the 1. or 2. day after surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients will be included the 1. or 2. day after surgery. All TKA patients will be
      screened. Those reporting VAS &gt; 60 during active 45 degrees knee flexion will be asked to
      participate.

      Included patients will receive 2xACB (singleshot) first placebo (30ml saline) and then
      ropivacaine (30ml ropivacaine 7,5mg/ml) or the other way around (randomized). There will be
      45 minutes between the two blockades. The blockades will be ultrasound guided.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in VAS between ACB and placebo during active 45 degrees knee flexion</measure>
    <time_frame>45 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in mean VAS between the groups during active knee flexion</measure>
    <time_frame>15, 30, 60, 75 and 90 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in mean VAS between the groups at rest</measure>
    <time_frame>15, 30, 60, 75 and 90 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Pain After Total Knee Arthroplasty</condition>
  <arm_group>
    <arm_group_label>Arm RP</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>first blockade: ropivacaine 7,5mg/ml 30 ml second blockade: placebo: saline 30 ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm PR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>first blockade: placebo: saline 30 ml second blockade: ropivacaine 7,5mg/ml 30 ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Arm RP is receiving 30 ml of ropivacaine 7,5 mg/ml at first blockade (ACB) and after 45 minutes another blockade (ACB) with placebo (saline 30 ml).
Arm PR is receiving 30 ml of placebo (saline) at first blockade (ACB) and after 45 minutes another blockade (ACB)with ropivacaine.</description>
    <arm_group_label>Arm RP</arm_group_label>
    <arm_group_label>Arm PR</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>please see intervention description for ropivacaine</description>
    <arm_group_label>Arm RP</arm_group_label>
    <arm_group_label>Arm PR</arm_group_label>
    <other_name>NaCl, placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  TKA within 48 hours and VAS&gt;60 during active 45 degrees knee flexion despite
             conventional pain medication.

          -  Informed consent

          -  ASA 1-3

          -  BMI 18-40

        Exclusion Criteria:

          -  Unable to communicate in Danish

          -  Allergic reactions toward drugs used in the

          -  Abuse of alcohol/drugs

          -  Unable to cooperate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrik Grevstad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gentofte Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2012</study_first_submitted>
  <study_first_submitted_qc>March 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2012</study_first_posted>
  <last_update_submitted>January 7, 2013</last_update_submitted>
  <last_update_submitted_qc>January 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Ulrik Grevstad</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>Total knee arthroplasty</keyword>
  <keyword>Adductor canal blockade (ACB)</keyword>
  <keyword>High pain responders</keyword>
  <keyword>US-guided nerve block</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

